Unlock the Potential of GPEx® Lightning: Accelerate Your HEK Cell Line Development

Discover the Lightning technology platform, now enhanced with the inclusion of HEK cell lines to complement our Lightning CHO cell line development. Achieve rapid, scalable, and flexible high-expressing cell lines for complex biologics. Save up to 12 weeks with our nonviral gene insertion technology.

Register Free: https://www.biopharminternational.com/bp_w/potential-of-lightning

Event Overview:

Join us for an insightful webinar where we unveil the latest advancements in Catalent's GPEx® Lightning technology platform, now featuring HEK cell lines. The cell line development technology platform revolutionizes the generation of complex biologics with unmatched speed, scalability, and flexibility. Learn how our collaborative services deliver exceptional performance, significantly reducing the production timeline for HEK cell lines while precisely expressing a variety of complex and challenging proteins. Our experts will present new data showcasing our proven success in transforming your biologic from gene to commercial success.

Key Learning Objectives:

• Explore how Catalent’s GPEx® Lightning technology platform, now including both HEK and CHO cell lines, can enhance your next project.
• Learn about the significant time savings of up to 12 weeks on development timelines with the use of nonviral gene insertion technology.
• Explore the high-quality production capabilities for antibodies, Fc fusion proteins, and recombinant proteins.

Who Should Attend:

• Chief scientific officers
• Process development scientists
• CMC engineers
• Upstream development scientists
• VP & director levels in biologic development, bioprocessing, biomanufacturing, bioproduction, and process development

Speaker:

Jessica Anderson, PhD
Senior Scientist Research and Development
Catalent Pharma Solutions

Jessica Anderson, PhD, is a senior scientist in research and development at Catalent Pharma Solutions, where she works closely with molecular biology, cell line, and process development. She received her PhD in biochemistry and molecular biology from Marquette University. She brings her 8 years of experience in cell line and media development to support the creation of new platforms at Catalent.

Register Free: https://www.biopharminternational.com/bp_w/potential-of-lightning